Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Biosensors Europe SA

Clinicaltrial registered16 Nov 2026

Biosensors Europe SA

16 Nov 2026: Trial registered · Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE). Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
16 Nov 2026
Title
Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)
Conditions
Angina (Stable), Unstable Angina (UA), NSTEMI
Phase
Early Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United Kingdom
Country
United Kingdom
Reference
NCT07938060
Location
United Kingdom
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Biosensors Europe SA

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United Kingdom

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.